As with any new technology in a heavily regulated industry, widespread adoption of blockchain technology in health care is highly dependent on striking the right balance between innovation and regulation. Finding that balance requires an understanding of both the technology and the regulatory boundaries.
Collaborations are common in drug development. In most cases, the partners have similar goals — to develop and market a product — but their sensitivities around public disclosures about the collaboration may be very different. Join partners Timothy C. Atkins and Scott R. Jones as they discuss issues that may arise in connection with the disclosure obligations of collaboration partners.